The Guardant360 NGS ctDNA assay (Guardant Health, Redwood City, CA, USA) includes TERT promoter mutations (47–50), but this pan-cancer panel is not adjustable or specifically tailored for melanoma and requires an allele frequency above 0.25% to detect mutations with 100% sensitivity. Here, TERT is linked to melanoma.